Selumetinib in Cancers With BRAF Mutations

Conditions

• Adult Solid Neoplasm

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Selumetinib — DRUG
  Given PO

Study Details

The purpose of this research study is to determine if selumetinib is safe and effective in treating patients with cancers with a mutated BRAF gene. Selumetinib is an investigational drug that works by blocking a protein called MEK, which is known to play a role in the growth of cancer cells lines and tumors that have a mutated BRAF gene. There are multiple types of cancers that have mutations in the BRAF gene and depend on the activity of this gene for their growth and survival.

Key Dates

Start date

Jul 31, 2009

Status verified

Jul 2015

Primary completion

Jan 31, 2015

Completion

Jan 31, 2015

Study Design

Enrollment

28 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (selumetinib)
  Patients receive selumetinib PO BID for 3 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Objective Response Rate in Patients With Cancers Other Than Melanoma [ Time Frame: 4 years ]

Locations (5)

Find similar trials in Boston, MA